Peringatan Keamanan

The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m².

Valrubicin

DB00385

small molecule approved

Deskripsi

Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR. It is a semisynthetic analog of the doxorubicin, which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.

Struktur Molekul 2D

Berat 723.651

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Valrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

40 Data

Trastuzumab	The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Valrubicin.
Margetuximab	The risk or severity of cardiotoxicity can be increased when Margetuximab is combined with Valrubicin.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valrubicin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Valrubicin.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Valrubicin.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valrubicin.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Lidocaine.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Ropivacaine.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Bupivacaine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Cinchocaine.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Dyclonine.
Procaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Procaine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Prilocaine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Proparacaine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Meloxicam.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Oxybuprocaine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Cocaine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Mepivacaine.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Levobupivacaine.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Diphenhydramine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Benzocaine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Chloroprocaine.
Phenol	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Phenol.
Tetrodotoxin	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Tetrodotoxin.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Benzyl alcohol.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Capsaicin.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Etidocaine.
Articaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Articaine.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Tetracaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Propoxycaine.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Pramocaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Butamben.
Butacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Butacaine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Oxetacaine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Ethyl chloride.
Butanilicaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Butanilicaine.
Metabutethamine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Metabutethamine.
Quinisocaine	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Quinisocaine.
Ambroxol	The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Ambroxol.
Etrasimod	The risk or severity of immunosuppression can be increased when Valrubicin is combined with Etrasimod.

Target Protein

DNA

DNA topoisomerase 2-beta TOP2B

DNA topoisomerase 2-alpha TOP2A

Referensi & Sumber

Synthesis reference: Francesca Scarpitta, Csilla Nemethne Racz, "Crystalline forms of valrubicin and processes for their preparation." U.S. Patent US20080139490, issued June 12, 2008.

Contoh Produk & Brand

Produk: 3 • International brands: 0

Produk

Valrubicin Intravesical Solution

Solution, concentrate • 40 mg/1mL • Intravesical • US • Generic • Approved
Valstar

Solution, concentrate • 40 mg/1mL • Intravesical • US • Approved
Valtaxin

Solution • 40 mg / mL • Intravesical • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.